Joincare Pharmaceutical Group IndustryLtd Past Earnings Performance
Past criteria checks 4/6
Joincare Pharmaceutical Group IndustryLtd has been growing earnings at an average annual rate of 10.5%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been growing at an average rate of 7.2% per year. Joincare Pharmaceutical Group IndustryLtd's return on equity is 12.9%, and it has net margins of 9.3%.
Key information
10.5%
Earnings growth rate
11.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 7.2% |
| Return on equity | 12.9% |
| Net Margin | 9.3% |
| Next Earnings Update | 25 Nov 2024 |
Recent past performance updates
Recent updates
Joincare Pharmaceutical Group Industry Co.,Ltd.'s (SHSE:600380) Business And Shares Still Trailing The Market
Aug 13
We Think Joincare Pharmaceutical Group IndustryLtd (SHSE:600380) Can Manage Its Debt With Ease
Jun 23Shareholders Will Probably Hold Off On Increasing Joincare Pharmaceutical Group Industry Co.,Ltd.'s (SHSE:600380) CEO Compensation For The Time Being
May 31Joincare Pharmaceutical Group IndustryLtd's (SHSE:600380) Conservative Accounting Might Explain Soft Earnings
Apr 09Investors Don't See Light At End Of Joincare Pharmaceutical Group Industry Co.,Ltd.'s (SHSE:600380) Tunnel
Mar 04Revenue & Expenses Breakdown
How Joincare Pharmaceutical Group IndustryLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 15,894 | 1,471 | 4,920 | 1,487 |
| 30 Jun 24 | 16,161 | 1,404 | 5,073 | 1,611 |
| 31 Mar 24 | 16,427 | 1,420 | 5,303 | 1,658 |
| 31 Dec 23 | 16,646 | 1,443 | 5,385 | 1,662 |
| 30 Sep 23 | 16,782 | 1,460 | 5,356 | 1,721 |
| 30 Jun 23 | 17,298 | 1,517 | 5,758 | 1,800 |
| 31 Mar 23 | 17,044 | 1,505 | 5,726 | 1,772 |
| 31 Dec 22 | 17,143 | 1,503 | 5,947 | 1,742 |
| 30 Sep 22 | 16,982 | 1,446 | 6,209 | 1,671 |
| 30 Jun 22 | 16,633 | 1,442 | 6,112 | 1,482 |
| 31 Mar 22 | 16,416 | 1,422 | 6,072 | 1,459 |
| 31 Dec 21 | 15,904 | 1,328 | 5,975 | 1,397 |
| 30 Sep 21 | 15,352 | 1,202 | 5,816 | 1,335 |
| 30 Jun 21 | 14,881 | 1,132 | 5,597 | 1,322 |
| 31 Mar 21 | 14,479 | 1,207 | 5,265 | 1,200 |
| 31 Dec 20 | 13,522 | 1,120 | 4,903 | 1,072 |
| 30 Sep 20 | 12,792 | 1,043 | 4,607 | 1,022 |
| 30 Jun 20 | 12,171 | 1,024 | 4,416 | 918 |
| 31 Mar 20 | 11,826 | 869 | 4,678 | 895 |
| 31 Dec 19 | 11,980 | 894 | 4,821 | 906 |
| 30 Sep 19 | 11,858 | 837 | 4,891 | 836 |
| 30 Jun 19 | 11,741 | 820 | 4,914 | 755 |
| 31 Mar 19 | 11,536 | 779 | 4,742 | 749 |
| 31 Dec 18 | 11,204 | 699 | 4,668 | 708 |
| 30 Sep 18 | 11,208 | 749 | 4,591 | 622 |
| 30 Jun 18 | 11,083 | 2,232 | 4,626 | 621 |
| 31 Mar 18 | 11,030 | 2,167 | 4,593 | 659 |
| 01 Jan 18 | 10,779 | 2,133 | 4,616 | 528 |
| 30 Sep 17 | 10,562 | 2,103 | 4,812 | 358 |
| 30 Jun 17 | 10,254 | 521 | 4,804 | 220 |
| 31 Mar 17 | 10,125 | 484 | 4,970 | 0 |
| 31 Dec 16 | 9,722 | 451 | 4,772 | 0 |
| 30 Sep 16 | 9,546 | 346 | 4,610 | 0 |
| 30 Jun 16 | 9,373 | 337 | 4,494 | 0 |
| 31 Mar 16 | 8,881 | 393 | 4,187 | 0 |
| 31 Dec 15 | 8,642 | 412 | 4,031 | 0 |
| 30 Sep 15 | 8,317 | 492 | 3,859 | 0 |
| 30 Jun 15 | 8,031 | 487 | 3,698 | 0 |
| 31 Mar 15 | 7,802 | 412 | 3,598 | 0 |
| 31 Dec 14 | 7,418 | 354 | 3,389 | 0 |
| 30 Sep 14 | 7,413 | 319 | 3,343 | 0 |
| 30 Jun 14 | 6,869 | 298 | 3,124 | 0 |
| 31 Mar 14 | 6,463 | 282 | 2,977 | 0 |
| 31 Dec 13 | 6,220 | 274 | 2,891 | 0 |
Quality Earnings: 600380 has high quality earnings.
Growing Profit Margin: 600380's current net profit margins (9.3%) are higher than last year (8.7%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 600380's earnings have grown by 10.5% per year over the past 5 years.
Accelerating Growth: 600380's earnings growth over the past year (0.7%) is below its 5-year average (10.5% per year).
Earnings vs Industry: 600380 earnings growth over the past year (0.7%) exceeded the Pharmaceuticals industry -1.2%.
Return on Equity
High ROE: 600380's Return on Equity (12.9%) is considered low.